Largest-Ever Study Of T-Wave Alternans Greeted With Skepticism
This article was originally published in The Gray Sheet
Executive Summary
Cambridge Heart hopes results from the largest study of its Microvolt T-Wave Alternans (MTWA) test will increase physician adoption of the technology, though the clinical community is holding out for more data
You may also be interested in...
Cambridge Heart Sees Strong Growth, Despite Blue Cross’ Negativity
The Blue Cross Blue Shield Association has reaffirmed its negative assessment of microvolt T-wave alternans testing to risk-stratify candidates for ICD therapy, despite accelerating market adoption that is driving sales growth for MTWA test maker Cambridge Heart
Cambridge Heart Sees Strong Growth, Despite Blue Cross’ Negativity
The Blue Cross Blue Shield Association has reaffirmed its negative assessment of microvolt T-wave alternans testing to risk-stratify candidates for ICD therapy, despite accelerating market adoption that is driving sales growth for MTWA test maker Cambridge Heart
T-Wave Test For ICD Need Has Different Role To Play For Healthier Patients
Microvolt T-Wave Alternans (MTWA) testing should not be used alone to determine whether a relatively healthy heart attack survivor should get an implantable defibrillator (ICD), but it is still useful as a first-line risk stratifier for sudden cardiac death, according to a new study